MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals

AIDS

Volumn 12, Issue 7, 1998, Pages 729-736

  Bratt, Göran ^a   Leandersson, Ann Charlotte ^b   Albert, Jan ^b   Sandström, Eric ^a   Wahren, Britta ^b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CCR 5; CD4; Coreceptors; Disease progression; MT 2; Viral phenotype; Virus entry

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DISEASE COURSE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SWEDEN;

ADULT; AGED; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; CELL LINE, TRANSFORMED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GENOTYPE; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, CCR5; RECOMBINANT PROTEINS; SEQUENCE DELETION; VACCINES, SYNTHETIC; VIRAL LOAD;

EID: 0032493007     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199807000-00009     Document Type: Article

References (42)

1. Schellekens PT, Koot M, Roos MT, Tersmette M, Miedema F: Immunologic and virologic markers determining progression to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10 (suppl 2):S62-S66.
2. Tersmette M, Lange JM, de Goede RE, et al.: Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989, i:983-985.
3. Åsjö B, Morfeldt-Månson L, Albert J, et al.: Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986, ii:660-662.
4. Levy JA: Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993, 57:183-289.
5. Asjo B, Sharma UK, Morfeldt-Manson L, et al.: Naturally occurring HIV-1 isolates with differences in replicative capacity are distinguished by in situ hybridization of infected cells. AIDS Res Hum Retroviruses 1990, 6:1177-1182.
6. Fenyö EM, Morfeldt-Månson L, Chiodi F, et al.: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988, 62:4414-4419.
7. Koot M, Vos AH, Keet RPM, et al.: HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992, 6:49-54.
8. Karlsson A, Parsmyr K, Sandström E, Fenyö EM, Albert J: MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994, 32:364-370.
9. Connor RI, Mohri H, Cao Y, Ho DD: Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 1993, 67:1772-1777.
10. Richman DD, Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994, 169:968-974.
11. Koot M, Schellekens PT, Mulder JW, et al.: Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. J Infect Dis 1993, 168:733-736.
12. Schellekens PTA, Tersmette M, Roos MTL, et al.: Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS 1992, 6:665-669.
13. Koot M, Keet IP, Vos AH, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681-688.
14. D'Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med 1995, 122:401-408.
15. Michael NL, Chang G, Louie LG, et a.: The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997, 3:338-340.
16. Choe H, Farzan M, Sun Y, et al.: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85:1135-1148.
17. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
18. Deng H, Liu R, Ellmeier W, et al.: Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
19. Alkhatib G, Combadiere C, Broder CC, et al.: CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
20. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877
21. Bratt G, Sandström E, Albert J, Samson M, Wahren B: The influence of MT-2 tropism on the prognostic implications of the 32 base-pair deletion in the CCR-5 gene. AIDS 1997, 11:1415-1419.
22. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR: Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997, 185:621-628.
23. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
24. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE. Science 1996, 273:1856-1862.
25. Huang Y, Paxton WA, Wolinsky SM, et al.: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996, 2:1240-1243.
26. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T: HIV-1 infection in an individual homozygous for the CCR5 deletion allele [letter]. Nature Med 1997, 3:252-253.
27. Balotta C, Bagnarelli P, Violin M, et al.: Homozygous Δ32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997, 11:F67-F71.
28. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C: HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group [letter]. Lancet 1997, 349:1219-1220.
29. O'Brien TR, Winkler C, Dean M, et al.: HIV-1 infection in a man homozygous for CCR5 delta 32 [letter]. Lancet 1997, 349:1219.
30. Eugen-Olsen J, Iversen AKN, Garred P, et al.: Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997, 11:305-310.
31. Rappaport J, Cho YY, Hendel H, Schwartz EJ, Schachter F, Zagury JF: 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes [letter]. Lancet 1997, 349:922-923.
32. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996, 276:146-154.
33. Scarlatti G, Lombardi V, Plebani A, et al.: Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children. AIDS 1991, 5:1173-1178.
34. Mehta CR, Patel NR, Tsiatis AA: Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 1984, 40:819-825.
35. Meyer L, Magierowska M, Hubert J, et al.: Early protective effect of CCR-5 Δ32/wild-type heterozygosity on HIV-1 disease progression: relationship with viral load. AIDS 1997, 11:F73-F78.
36. Bozzette SA, McCutchan JA, Spector SA, Wright B, Richman DD: A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis 1993, 168:1374-1379.
37. Karlsson A, Parsmyr K, Aperia K, Sandström E, Fenyö EM, Albert J: MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. J Infect Dis 1994, 170:1367-1375.
38. Ercoli L, Sarmati L, Nicastri E, et al.: HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity. AIDS 1997, 11:1211-1217.
39. Kuritzkes DR, Quinn JB, Benoit SL, et al.: Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
40. Simmons G, Wilkinson D, Reeves JD, et al.: Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 1996, 70:8355-8360.
41. Moore JP: Coreceptors: implications for HIV pathogenesis and therapy. Science 1997, 276:51-52.
42. Trkola A, Dragic T, Arthos J, et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187.